"Designer Drugs" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs designed and synthesized, often for illegal street use, by modification of existing drug structures (e.g., amphetamines). Of special interest are MPTP (a reverse ester of meperidine), MDA (3,4-methylenedioxyamphetamine), and MDMA (3,4-methylenedioxymethamphetamine). Many drugs act on the aminergic system, the physiologically active biogenic amines.
| Descriptor ID |
D015198
|
| MeSH Number(s) |
D26.200
|
| Concept/Terms |
Designer Drugs- Designer Drugs
- Drugs, Designer
- Customized Drugs
- Drugs, Customized
|
Below are MeSH descriptors whose meaning is more general than "Designer Drugs".
Below are MeSH descriptors whose meaning is more specific than "Designer Drugs".
This graph shows the total number of publications written about "Designer Drugs" by people in this website by year, and whether "Designer Drugs" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2011 | 1 | 0 | 1 |
| 2015 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Designer Drugs" by people in Profiles.
-
Ferrari LL, Ogbeide-Latario OE, Gompf HS, Anaclet C. Validation of DREADD agonists and administration route in a murine model of sleep enhancement. J Neurosci Methods. 2022 Oct 01; 380:109679.
-
Riederer AM, Campleman SL, Carlson RG, Boyer EW, Manini AF, Wax PM, Brent JA. Acute Poisonings from Synthetic Cannabinoids - 50 U.S. Toxicology Investigators Consortium Registry Sites, 2010-2015. MMWR Morb Mortal Wkly Rep. 2016 Jul 15; 65(27):692-5.
-
You IJ, Wright SR, Garcia-Garcia AL, Tapper AR, Gardner PD, Koob GF, David Leonardo E, Bohn LM, Wee S. 5-HT1A Autoreceptors in the Dorsal Raphe Nucleus Convey Vulnerability to Compulsive Cocaine Seeking. Neuropsychopharmacology. 2016 Apr; 41(5):1210-22.
-
Aoun EG, Christopher PP, Ingraham JW. Emerging drugs of abuse: clinical and legal considerations. R I Med J (2013). 2014 Jun 02; 97(6):41-5.
-
Wang D, Belakhov V, Kandasamy J, Baasov T, Li SC, Li YT, Bedwell DM, Keeling KM. The designer aminoglycoside NB84 significantly reduces glycosaminoglycan accumulation associated with MPS I-H in the Idua-W392X mouse. Mol Genet Metab. 2012 Jan; 105(1):116-25.